The Case for Continuing to Study Birth Weight in Retinopathy of Prematurity Research

Acta Paediatrica 2026 Open access

Read full text
Authors: Cindy S. Zhao, Eugenia C. Greig, Darius M. Moshfeghi
DOI: 10.1111/apa.70605
Cited by: 1
References: 2

Abstract

D.M.M.– Ainsly Limited (E), Akebia (SAB), Alexion (C), Boehringer Ingelheim (C), Clinical Trials Resource Group (SAB), Clinical Trials Summit (H), dSentz Inc. (F, E, BOD), Feliqs Inc. (C), Icon (C, DSMB), InGel Therapeutics (DSMB), Insite DME (C), Ocular Therapeutix (C, E), Osanni Bio (C, E), Plenoptika Inc. (E), Pr3vent Inc. (F, E, BOD), Pykus (E), RetinaBio Inc. (E), Vanotech Chengdu (C), Vision Labs Ai Inc. (F, E), Promisight Inc. (E, disbanded), Grand Legend Technology Ltd. (E, defunct), Visunex (E, defunct), research to prevent blindness Inc. (G), NEI P30-EY026877 (G). Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Fields of Study & Subjects

Retinopathy of Prematurity Studies Neonatal and fetal brain pathology Preterm Birth and Chorioamnionitis

Publication details

Journal / source
Acta Paediatrica
Publisher
Wiley
Volume
115
Issue
9
Pages
2034–2035
Publication date
25 May 2026
Language
EN